In silico identifying MET/FN1/TGFBI as molecular targets in drug-resistant head and neck cancer and preclinical repurposing sulfasalazine for enhanced therapeutic efficacy

In silico identifying MET/FN1/TGFBI as molecular targets in drug-resistant head and neck cancer and preclinical repurposing sulfasalazine for enhanced therapeutic efficacy

Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive cancer affecting over half a million people worldwide each year. Although recent FDA-approved treatments, like cetuximab, have shown promise, the five-year survival rate remains below 50 %. This underscores the need to identify mol...

Full description

Bibliographic Details
Main Authors: Ntlotlang Mokgautsi, Alexander TH Wu, Sheng-Yao Cheng, Jih-Chin Lee, Thomashire Anita George, Jia-Hong Chen
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Arabian Journal of Chemistry
Subjects:
Head and neck squamous cell carcinoma (HNSCC)
Cisplatin resistance
cancer-associated fibroblasts (CAF)
Sulfasalazine
Online Access:http://www.sciencedirect.com/science/article/pii/S1878535223010237

Internet

http://www.sciencedirect.com/science/article/pii/S1878535223010237

Similar Items